Marketing-authorisation holder · United States
Pf Prism Cv
15 medicines in 1 country, as authorisation holder.
Group structure
Part of
PrismPharmaceutical groupOther companies in the group
Canada1
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Medicines
Every medicine in the registers under its name, current ones first.
15 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| BOSULIF100mg base | 50mg base · Capsule | Bosutinib | United States | Marketed | 2023 |
| BOSULIF100mg base | 400mg base | 500mg base · Tablet | Bosutinib | United States | Marketed | 2012 |
| CHANTIX0.5mg base | 1mg base · Tablet | Varenicline | United States | Marketed | 2006 |
| INLYTA1mg | 5mg · Tablet | Axitinib | United States | Marketed | 2012 |
| PRISTIQ100mg base | 25mg base | 50mg base · Tablet, extended release | Desvenlafaxine | United States | Marketed | 2008 |
| RAPAMUNE1mg/ml · Solution | Sirolimus | United States | Marketed | 1999 |
| RAPAMUNE0.5MG | 1MG | 2MG | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Sirolimus | United States | Marketed | 2000 |
| TORISEL25mg/ml (25mg/ml) · Solution | Temsirolimus | United States | Marketed | 2007 |
| TYGACIL50mg/vial · Powder | Tigecycline | United States | Marketed | 2005 |
| VFEND200mg/vial · Powder | Voriconazole | United States | Marketed | 2002 |
| VFEND200mg/5ml · For suspension | Voriconazole | United States | Marketed | 2003 |
| XALKORI200mg | 250mg · Capsule | Crizotinib | United States | Marketed | 2011 |
| XALKORI150mg | 20mg | 50mg · Capsule, pellets | Crizotinib | United States | Marketed | 2023 |
| XELJANZ10mg base | 5mg base · Tablet | Tofacitinib | United States | Marketed | 2012 |
| ZMAX2gm base/bot · For suspension, extended release | Azithromycin | United States | Not marketed | 2005 |